Filter by
Search QAs (2169)
RSS1619
Can EIOPA provide practical examples for appropriate product testing?
1620
Are manufacturers expected to rectify any circumstances that could have an adverse effect for customers?
1621
In which intervals are manufacturers of insurance products expected to review their products?
1616
Are manufacturers of insurance products expected to identify the target market where insurance products are targeted to legal persons?
1617
How would the Product Oversight and Governance requirements apply in the context of group insurance contracts?
1618
What action are manufacturers expected to take if products are distributed to customers outside of the target market? Examples of appropriate action?
1615
Are manufacturers of insurance products expected to apply the Product Oversight and Governance requirements with regard to insurance products which are distributed by ancillary insurance intermediaries exempted from the scope of the IDD?
1614
How can the manufacturer demonstrate that they have taken into account the level of information available to customers and the financial literacy of customers?
1612
Can EIOPA provide more guidance on how to assess the granularity of the target market?
1903
For investments in private equity funds there is normally not possible to report Quantity in C0130, S.06.02 List of assets. Can it be wise to report just 1.0 in C0130/Quantity or should the cell be left empty?